Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children's Oncology Group
Children's Oncology Group
Dana-Farber Cancer Institute
Phoenix Children's Hospital
Dana-Farber Cancer Institute
Children's Oncology Group
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
Sanofi
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Therapeutic Advances in Childhood Leukemia Consortium
University Hospital Schleswig-Holstein
Children's Oncology Group
Children's Oncology Group
Aarhus University Hospital
Goethe University
Goethe University
Goethe University
Goethe University
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Gruppo Italiano Malattie EMatologiche dell'Adulto
ERYtech Pharma
Gruppo Italiano Malattie EMatologiche dell'Adulto
Children's Oncology Group
Therapeutic Advances in Childhood Leukemia Consortium
St. Jude Children's Research Hospital
Aristotle University Of Thessaloniki
National Cancer Institute (NCI)
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Children's Oncology Group
Therapeutic Advances in Childhood Leukemia Consortium
Gruppo Italiano Malattie EMatologiche dell'Adulto
Asan Medical Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Children's Oncology Group
National Cancer Institute (NCI)
National University Hospital, Singapore
Alliance for Clinical Trials in Oncology
PETHEMA Foundation
National Cancer Institute (NCI)
SWOG Cancer Research Network
University Hospital, Lille
M.D. Anderson Cancer Center
Children's Oncology Group